On August 27, 2018, Knowledge Ecology International (KEI) and the Union for Affordable Cancer Treatment (UACT) filed comments to the NIH regarding the prospective grant of two separate exclusive licenses to Sinotau Pharmaceutical Group and Molecular Targeting Technologies, Inc. (MTTI),… Continue Reading
On August 20, 2018, KEI and T1International filed comments to the NIH regarding the prospective grant of an exclusive license to Inversago Pharma, a firm headquartered in Canada. According to the Federal Register notice 83 FR 38707, the NIH exclusive… Continue Reading
(Update: The NIH provided a response to our comments on August 1, 2020) July 10, 2018 Sury Vepa, Ph.D., J.D., Senior Licensing and Patenting Manager National Center for Advancing Translational Sciences National Institutes of Health Email sury.vepa@nih.gov Re: Prospective Grant… Continue Reading
On July 9, 2018, KEI asked the NIH to extend the deadline for comments described on the Federal Register notice 83 FR 30448 until information about the enrollment and costs of NIH-funded clinical trials involving mesothelin expressing cancers, and trials… Continue Reading
Today Knowledge Ecology International (KEI), the Union for Affordable Cancer Treatment (UACT), Health GAP, Social Security Works (SSW), People of Faith for Access to Medicines (PFAM), Universities Allied for Essential Medicines (UAEM) and Dean Baker filed comments to the National… Continue Reading
On June 8, 2018 the Cámara de Diputados of the Chilean Congress overwhelmingly passed a resolution calling on the Ministry of Health to proceed with compulsory licenses on patents covering hepatitis C virus (HCV) drugs. Resolution No. 68, passed with… Continue Reading